By	O
inhibiting	O
IL-1α	B
AAA	I
BBB	I
/	O
IL-1β	B
competitively	O
from	O
binding	O
to	O
the	O
IL-1	B
type-	O
I	B
receptor	I
,	O
anakinra	O
,	O
neutralizes	O
the	O
activity	O
that	O
pertains	O
to	O
these	O
key	O
mediators	O
of	O
autoinflammatory	O
and/or	O
immune	O
processes	O
.	O

Clinical	O
outcomes	O
of	O
those	O
who	O
use	O
an	O
ACE	B
inhibitor	O
(	O
ACEI	O
)	O
or	O
angiotensin	B
II	I
type-	O
I	B
receptor	I
blocker	O
(	O
ARB	O
)	O
were	O
comparable	O
with	O
those	O
of	O
patients	O
who	O
do	O
not	O
use	O
ACEI/ARB	O
among	O
COVID-19	O
patients	O
with	O
diabetes	O
and	O
hypertension	O
.	O

Patients	O
taking	O
angiotensin-converting	B
enzyme	I
inhibitors/	O
angiotensin	B
II	I
type	O
I	B
receptor	I
blockers	O
:	O
higher	O
risks	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
2	O
infection	O
but	O
milder	O
clinical	O
manifestations	O
?	O

Avoiding	O
the	O
prescription	O
of	O
non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
angiotensin	B
converting	I
enzyme	I
inhibitors	O
,	O
or	O
angiotensin	B
II	I
type	O
I	B
receptor	I
blockers	O
is	O
advised	O
for	O
COVID-19	O
AAA	O
BB	O
CCC	O
patients	O
.	O

